Therapy Detail

Therapy Name Lirilumab
Synonym
Therapy Description

Lirilumab is a monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), which leads to increased NK cell-mediated cytotoxicity towards tumor cells (PMID: 24326534).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Lirilumab IPH2102|BMS-986015 Lirilumab is a monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), which leads to increased NK cell-mediated cytotoxicity towards tumor cells (PMID: 24326534).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01592370 Phase I Nivolumab Ipilimumab Lirilumab Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma Recruiting
NCT02252263 Phase I Urelumab Lirilumab Elotuzumab A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma Completed
NCT02599649 Phase II Nivolumab Azacitidine Lirilumab Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) Completed